In addition, CTHRC1 promoted M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by the integrin-Akt signaling pathway, which indicated that CTHRC1 might be a biomarker for tumor immunotherapy (Li L. Y. et al., 2019). This evidence concerns the gene AKT1 and neoplasm.